SEA-Immun-132 Distribution: General

## 12th Meeting of the South-East Asia Regional Certification Commission for Polio Eradication (SEA-RCCPE)

Dhaka, Bangladesh, 18-19 September 2019



12th Meeting of the South-East Asia Regional Certification Commission for Polio Eradication (SEA-RCCPE) SEA-Immun-132

## © World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. 12th Meeting of the South-East Asia Regional Certification Commission for Polio Eradication (SEA-RCCPE). New Delhi: World Health Organization, Regional Office for South-East Asia; 2018. License: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## **Contents**

	Page
Abb	previationsv
1.	Introduction
2.	Opening2
3.	Global progress in polio eradication and Polio Endgame Strategy 2019-2023
4.	Update from the WHO Regional Office of the Eastern Mediterranean:
5.	Update from WHO Regional Office for the Western Pacific:
6.	Regional update on maintaining polio-free status
7.	Conclusions, observations and general recommendations
8.	Country specific conclusions and recommendations
	Annexes
1.	Agenda13
2.	List of participants

## **Abbreviations**

AFP acute flaccid paralysis

bOPV bivalent oral poliovirus vaccine
CCS containment certification scheme

CP certificate of participation

cVDPV circulating vaccine-derived poliovirus

cVDPV1 circulating vaccine-derived poliovirus type 1 cVDPV2 circulating vaccine-derived poliovirus type 2

Endgame Plan Polio Eradication & Endgame Strategic Plan 2013-2018

GAPIII WHO global action plan to minimize poliovirus facility-associated risk

after type-specific eradication of wild polioviruses and sequential cessation

of oral polio vaccine use

GCC Global Certification Commission
GPEI Global Polio Eradication Initiative
IHR International Health Regulations
IPV inactivated poliovirus vaccine
mOPV2 monovalent OPV type 2

NAC national authority for containment

NCCPE National Certification Committee for Polio Eradication

NCTF National Containment Taskforce

nOPV2 novel monovalent mOPV2
OPV oral poliovirus vaccine
PEF poliovirus essential facility
PIM potentially infectious materials

RCCPE Regional Certification Commission for Polio Eradication

SEA South-East Asia

SEARO World Health Organization Regional Office for South-East Asia

SIA supplementary immunization activity

tOPV trivalent oral poliovirus vaccine

VDPV vaccine-derived poliovirus

VDPV2 vaccine-derived poliovirus type 2

WHO World Health Organization

WPV wild poliovirus

WPV1 wild poliovirus type 1 WPV2 wild poliovirus type 2 WPV3 wild poliovirus type 3



https://www.yunbaogao.cn/report/index/report?reportId=5\_24475

